Oruka shareholders approve Series A conversion and adjournment proposals

Oruka Therapeutics, Inc.

30,598,476 shares voted for Series A conversion; 6,026 against; 1,089 abstaining; no broker non-votes.
29,294,720 shares voted for adjournment proposal; 1,309,805 against; 1,066 abstaining.
Both proposals approved at special meeting held November 14, 2024.
Conversion involves Series A Non-Voting Convertible Preferred Stock issued September 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.